Through ANZGOG the PRECISE trial will engage with high grade serous ovarian cancer (HGSOC) patients who are found to possess reactivated cancer cells after treatment.
This is a common occurrence, as most HGSOC patients will relapse after chemotherapy and PARP inhibitor (PARPi) treatment, and develop a resistance to further treatment. The trial will aim to overcome the mechanisms that cause this resistance through the use of a novel oral PARP inhibitor known as Pamiparib.
The coordinating Principal Investigator of the trial is Dr. Ali Freimund, a medical oncologist at the Peter MacCallum Cancer Centre. Dr. Freimund says there is excitement around this trial and is hopeful that the trial will achieve positive outcomes for participants through the use of an ‘oral, well-tolerated drug that we’re very familiar with using in Australia.’
Participants in the trial will have an absence of a BRCA1/2 reversion, are found to have the presence of an ABCB1 fusion, are platinum sensitive or resistant and have already been treated with specific chemotherapies or oral PARPi.
Dr. Freimund believes that to identify the 40 patients required for the study, genetic testing of reactivated cancer cells from 200 patients will be performed to determine suitability for the trial.
“We’re hopeful that the use of a well-tolerated oral drug will achieve positive outcomes for participants.”
As more research aims to identify the causes of resistance to existing treatments in HGSOC patients, researchers are hopeful that the results of this study will provide insight into predicting how future patients will respond to combined PARPi and chemotherapy treatment.
Researchers believe the study will guide further research, answer other important unknown clinical questions, improve rates of HGSOC survival and assist in the development of future clinical trials.
The PRECISE trial is currently recruiting from the following sites:
- Peter MacCallum Cancer Centre, VIC
- Monash Medical Centre, VIC
- Prince of Wales Hospital, NSW
- Royal Hospital for Women, NSW
- Calvary Mater Newcastle, NSW
- Macarthur Cancer Therapy Centre, NSW
- Mater Brisbane Hospital, QLD
- Sir Charles Gairdner Hospital, WA
If you believe that you may be a suitable candidate, please speak to your Medical Oncologist about your eligibility.
For more information, please click here.